Skip to content

CDR

Endo makes changes to executive team

Endo makes changes to executive team

Endo International plc has announced executive changes in its U.S. branded drug and research-and-development units. Endo said Patrick Barry has been appointed as senior vice president of U.S.

Fred’s poised to be chain drug player

Fred’s poised to be chain drug player

Though Fred’s name came up in the buzz surrounding the Walgreens-Rite Aid merger talks with the FTC, the Southeastern retailer’s move to buy 865 Rite Aid stores for $950 million in cash from Walgreens Boots Alliance (WBA) still was surprising.

Huggies first to offer buy-in-bulk for diaper banks

Huggies first to offer buy-in-bulk for diaper banks

Early next year, Huggies plans to launch a program enabling diaper banks to buy bulk quantities of its diapers at competitive prices. The Kimberly-Clark baby care brand said Thursday that it will be the first global diaper brand to offer such a program.

Rite Aid sales, earnings decline in third quarter

Rite Aid sales, earnings decline in third quarter

Rite Aid Corp. said slim reimbursement rates, new generic drugs and the ongoing antitrust talks for the merger with Walgreens Boots Alliance (WBA) squeezed sales and earnings for its fiscal 2017 third quarter. Rite Aid said Thursday that for the third quarter ended Nov. 26, sales dipped 0.8% to $8.

ASOP leads effort targeting illegal online pharmacies

ASOP leads effort targeting illegal online pharmacies

The Alliance for Safe Online Pharmacies (ASOP Global) has partnered with the American Medical Association (AMA), American Pharmacists Association (APhA) and 14 other national health care stakeholders to educate providers and patients about the surge in illegal online pharmacies and counterfeit medic

Upsher-Smith sells AmLactin to Sandoz

Upsher-Smith sells AmLactin to Sandoz

Upsher-Smith Laboratories Inc. has entered an agreement to sell its AmLactin skin care brand to Sandoz Inc. Financial terms of the deal weren’t disclosed. Upsher-Smith said the move is part of its strategy of focusing on generic drugs and novel ­therapies.